Pharma Two B Announces Last Patient Out in Phase III Study of P2B001 in Early Parkinson’s Disease

[Farooqji]

P2B001 is a synergistic combination of low doses proprietary extended-release (ER) rasagiline (monoamine oxidase-B inhibitor) and pramipexole (dopamine agonist), both approved drugs for PD, designed to address an unmet medical need, being highly effective with minimal side effects, especially for early-stage patients. It has been formulated in a convenient, once-daily pill, with no titration required.

finance.yahoo.com/news/phar...

[laglag]

I'm interested in their definition of "early-stage" patients.

[Farooqji in reply to laglag]

"with disease duration less than 3 years since diagnosis."

clinicaltrials.gov/ct2/show...

[laglag in reply to Farooqji]

I missed that. Thanks for your reply.

[Hidden]

healthunlocked.com/cure-par...